Shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $64.06 and traded as low as $60.95. ProShares Ultra Nasdaq Biotechnology shares last traded at $63.13, with a volume of 4,575 shares trading hands.
ProShares Ultra Nasdaq Biotechnology Price Performance
The company has a 50-day simple moving average of $63.98 and a 200-day simple moving average of $61.29.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The company also recently declared a dividend, which was paid on Wednesday, October 2nd. Investors of record on Wednesday, September 25th were issued a $0.1528 dividend. This is a boost from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.04. The ex-dividend date was Wednesday, September 25th.
Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology
A hedge fund recently bought a new stake in ProShares Ultra Nasdaq Biotechnology stock. Texas Capital Bank Wealth Management Services Inc purchased a new stake in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm purchased 5,000 shares of the exchange traded fund's stock, valued at approximately $288,000. Texas Capital Bank Wealth Management Services Inc owned 0.31% of ProShares Ultra Nasdaq Biotechnology at the end of the most recent reporting period.
About ProShares Ultra Nasdaq Biotechnology
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Read More
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
